Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
50
FSNUF Quote, Financials, Valuation and Earnings
Last price:
$55.90
Seasonality move
:
4.06%
Day range:
$55.90 - $55.90
52-week range:
$32.85 - $58.16
Dividend yield:
2.03%
P/E ratio:
24.73x
P/S ratio:
1.28x
P/B ratio:
1.44x
Volume:
--
Avg. volume:
121
1-year change:
61.3%
Market cap:
$31.5B
Revenue:
$23.6B
EPS (TTM):
$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FSNUF
Fresenius SE & Co. KGaA
|
-- | -- | -- | -- | -- |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.04% | -86.85% | $138.33 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
EVO
Evotec SE
|
$219.8M | -$0.01 | 17.8% | -75.1% | $5.4436 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.87% | -704.25% | $18.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FSNUF
Fresenius SE & Co. KGaA
|
$55.90 | -- | $31.5B | 24.73x | $1.14 | 2.03% | 1.28x |
|
BNTX
BioNTech SE
|
$92.50 | $138.33 | $22.2B | 191.55x | $0.00 | 0% | 6.29x |
|
CVAC
CureVac NV
|
$4.16 | $5.31 | $936.7M | 5.82x | $0.00 | 0% | 11.56x |
|
EVO
Evotec SE
|
$2.9500 | $5.4436 | $1B | -- | $0.00 | 0% | 1.26x |
|
IFRX
InflaRx NV
|
$1.11 | $11.24 | $75.2M | -- | $0.00 | 0% | 342.97x |
|
IMTX
Immatics NV
|
$10.27 | $18.75 | $1.2B | 42.21x | $0.00 | 0% | 13.72x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FSNUF
Fresenius SE & Co. KGaA
|
42.1% | 1.498 | 48.29% | 0.68x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
EVO
Evotec SE
|
37.72% | 1.505 | 44.12% | 1.05x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FSNUF
Fresenius SE & Co. KGaA
|
$1.5B | $543.4M | 4.35% | 7.33% | 8.48% | $546.1M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
EVO
Evotec SE
|
-$72.4K | -$59.7M | -11.62% | -17.7% | -31.17% | -$101.3M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Fresenius SE & Co. KGaA vs. Competitors
-
Which has Higher Returns FSNUF or BNTX?
BioNTech SE has a net margin of 6.62% compared to Fresenius SE & Co. KGaA's net margin of -1.89%. Fresenius SE & Co. KGaA's return on equity of 7.33% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital FSNUFFresenius SE & Co. KGaA23.7% $0.71 $38.5B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About FSNUF or BNTX?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $138.33 which suggests that it could grow by 49.55%. Given that BioNTech SE has higher upside potential than Fresenius SE & Co. KGaA, analysts believe BioNTech SE is more attractive than Fresenius SE & Co. KGaA.
Company Buy Ratings Hold Ratings Sell Ratings FSNUFFresenius SE & Co. KGaA0 0 0 BNTXBioNTech SE14 5 0 -
Is FSNUF or BNTX More Risky?
Fresenius SE & Co. KGaA has a beta of 0.646, which suggesting that the stock is 35.399% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock FSNUF or BNTX?
Fresenius SE & Co. KGaA has a quarterly dividend of $1.14 per share corresponding to a yield of 2.03%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius SE & Co. KGaA pays 119.59% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FSNUF or BNTX?
Fresenius SE & Co. KGaA quarterly revenues are $6.4B, which are larger than BioNTech SE quarterly revenues of $1.8B. Fresenius SE & Co. KGaA's net income of $424.2M is higher than BioNTech SE's net income of -$33.5M. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 24.73x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.28x versus 6.29x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUFFresenius SE & Co. KGaA1.28x 24.73x $6.4B $424.2M BNTXBioNTech SE6.29x 191.55x $1.8B -$33.5M
-
Which has Higher Returns FSNUF or CVAC?
CureVac NV has a net margin of 6.62% compared to Fresenius SE & Co. KGaA's net margin of -5832.47%. Fresenius SE & Co. KGaA's return on equity of 7.33% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital FSNUFFresenius SE & Co. KGaA23.7% $0.71 $38.5B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About FSNUF or CVAC?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 27.96%. Given that CureVac NV has higher upside potential than Fresenius SE & Co. KGaA, analysts believe CureVac NV is more attractive than Fresenius SE & Co. KGaA.
Company Buy Ratings Hold Ratings Sell Ratings FSNUFFresenius SE & Co. KGaA0 0 0 CVACCureVac NV1 3 0 -
Is FSNUF or CVAC More Risky?
Fresenius SE & Co. KGaA has a beta of 0.646, which suggesting that the stock is 35.399% less volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock FSNUF or CVAC?
Fresenius SE & Co. KGaA has a quarterly dividend of $1.14 per share corresponding to a yield of 2.03%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius SE & Co. KGaA pays 119.59% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FSNUF or CVAC?
Fresenius SE & Co. KGaA quarterly revenues are $6.4B, which are larger than CureVac NV quarterly revenues of $63.3M. Fresenius SE & Co. KGaA's net income of $424.2M is higher than CureVac NV's net income of $319.3M. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 24.73x while CureVac NV's PE ratio is 5.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.28x versus 11.56x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUFFresenius SE & Co. KGaA1.28x 24.73x $6.4B $424.2M CVACCureVac NV11.56x 5.82x $63.3M $319.3M
-
Which has Higher Returns FSNUF or EVO?
Evotec SE has a net margin of 6.62% compared to Fresenius SE & Co. KGaA's net margin of -26.29%. Fresenius SE & Co. KGaA's return on equity of 7.33% beat Evotec SE's return on equity of -17.7%.
Company Gross Margin Earnings Per Share Invested Capital FSNUFFresenius SE & Co. KGaA23.7% $0.71 $38.5B EVOEvotec SE-0.04% -$0.14 $1.5B -
What do Analysts Say About FSNUF or EVO?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 85.23%. Given that Evotec SE has higher upside potential than Fresenius SE & Co. KGaA, analysts believe Evotec SE is more attractive than Fresenius SE & Co. KGaA.
Company Buy Ratings Hold Ratings Sell Ratings FSNUFFresenius SE & Co. KGaA0 0 0 EVOEvotec SE1 0 0 -
Is FSNUF or EVO More Risky?
Fresenius SE & Co. KGaA has a beta of 0.646, which suggesting that the stock is 35.399% less volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.
-
Which is a Better Dividend Stock FSNUF or EVO?
Fresenius SE & Co. KGaA has a quarterly dividend of $1.14 per share corresponding to a yield of 2.03%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius SE & Co. KGaA pays 119.59% of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FSNUF or EVO?
Fresenius SE & Co. KGaA quarterly revenues are $6.4B, which are larger than Evotec SE quarterly revenues of $191.5M. Fresenius SE & Co. KGaA's net income of $424.2M is higher than Evotec SE's net income of -$50.3M. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 24.73x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.28x versus 1.26x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUFFresenius SE & Co. KGaA1.28x 24.73x $6.4B $424.2M EVOEvotec SE1.26x -- $191.5M -$50.3M
-
Which has Higher Returns FSNUF or IFRX?
InflaRx NV has a net margin of 6.62% compared to Fresenius SE & Co. KGaA's net margin of -51538.49%. Fresenius SE & Co. KGaA's return on equity of 7.33% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital FSNUFFresenius SE & Co. KGaA23.7% $0.71 $38.5B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About FSNUF or IFRX?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 912.95%. Given that InflaRx NV has higher upside potential than Fresenius SE & Co. KGaA, analysts believe InflaRx NV is more attractive than Fresenius SE & Co. KGaA.
Company Buy Ratings Hold Ratings Sell Ratings FSNUFFresenius SE & Co. KGaA0 0 0 IFRXInflaRx NV5 2 0 -
Is FSNUF or IFRX More Risky?
Fresenius SE & Co. KGaA has a beta of 0.646, which suggesting that the stock is 35.399% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock FSNUF or IFRX?
Fresenius SE & Co. KGaA has a quarterly dividend of $1.14 per share corresponding to a yield of 2.03%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius SE & Co. KGaA pays 119.59% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FSNUF or IFRX?
Fresenius SE & Co. KGaA quarterly revenues are $6.4B, which are larger than InflaRx NV quarterly revenues of $27.8K. Fresenius SE & Co. KGaA's net income of $424.2M is higher than InflaRx NV's net income of -$14.3M. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 24.73x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.28x versus 342.97x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUFFresenius SE & Co. KGaA1.28x 24.73x $6.4B $424.2M IFRXInflaRx NV342.97x -- $27.8K -$14.3M
-
Which has Higher Returns FSNUF or IMTX?
Immatics NV has a net margin of 6.62% compared to Fresenius SE & Co. KGaA's net margin of -974.45%. Fresenius SE & Co. KGaA's return on equity of 7.33% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital FSNUFFresenius SE & Co. KGaA23.7% $0.71 $38.5B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About FSNUF or IMTX?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 82.57%. Given that Immatics NV has higher upside potential than Fresenius SE & Co. KGaA, analysts believe Immatics NV is more attractive than Fresenius SE & Co. KGaA.
Company Buy Ratings Hold Ratings Sell Ratings FSNUFFresenius SE & Co. KGaA0 0 0 IMTXImmatics NV9 0 0 -
Is FSNUF or IMTX More Risky?
Fresenius SE & Co. KGaA has a beta of 0.646, which suggesting that the stock is 35.399% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock FSNUF or IMTX?
Fresenius SE & Co. KGaA has a quarterly dividend of $1.14 per share corresponding to a yield of 2.03%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius SE & Co. KGaA pays 119.59% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FSNUF or IMTX?
Fresenius SE & Co. KGaA quarterly revenues are $6.4B, which are larger than Immatics NV quarterly revenues of $6.1M. Fresenius SE & Co. KGaA's net income of $424.2M is higher than Immatics NV's net income of -$59.1M. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 24.73x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.28x versus 13.72x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUFFresenius SE & Co. KGaA1.28x 24.73x $6.4B $424.2M IMTXImmatics NV13.72x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
